Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alvotech (ALVO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.76-0.22 (-3.15%)
At close: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

    Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and six biosimilar candidates REYKJAVIK, Iceland and BAD VILBEL, Germany, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and STADA Arzneimittel AG (STADA), announced today the laun

  • GlobeNewswire

    Alvotech Reports Update on Initial AVT02 Biologics License Application

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S. Food and Drug Administration (FDA) detailing its assessment of the March 2022 inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland and Alvotech’s subsequent written responses to the FDA. The FDA’s Complete Response Letter to the initial biosimilar Biologics License Appl

  • GlobeNewswire

    Alvotech Reports First Half 2022 Financial Results and Business Update

    Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as publicly-traded company on Nasdaq Stock Exchange in U.S. and on Nasdaq First North Market in Iceland; Board approved plan to move Iceland listing to Nasdaq Main MarketRevenues for first half 2022 increased to $40 million driven by revenue from milestones related to pipeline progress and recent launch

Advertisement
Advertisement